SGLT2 Is Tied to Fewer Post-MI Deaths in T2D SGLT2 Is Tied to Fewer Post-MI Deaths in T2D
Observational registry data from Sweden showed a significant link between SGLT2 inhibitor use at the time of an MI in people with type 2 diabetes and fewer all-cause deaths in 1-year follow-up.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - October 4, 2023 Category: Cardiology Tags: Cardiology News Source Type: news
SGLT2i Tied to Fewer Post-MI Deaths in T2D SGLT2i Tied to Fewer Post-MI Deaths in T2D
Observational registry data from Sweden showed a significant link between SGLT2 inhibitor use at the time of an MI in people with type 2 diabetes and fewer all-cause deaths in 1-year follow-up.Medscape Medical News (Source: Medscape Emergency Medicine Headlines)
Source: Medscape Emergency Medicine Headlines - October 4, 2023 Category: Emergency Medicine Tags: Cardiology News Source Type: news
Sep 29 2023 This Week in Cardiology Sep 29 2023 This Week in Cardiology
Reader feedback, leadless pacing, ABIM, SGLT2 inhibitors, peri-operative MI after cardiac surgery, and. AHA late-breakers are the topics John Mandrola, MD, covers in this week ’s podcast.theheart.org on Medscape (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - September 29, 2023 Category: Surgery Tags: Cardiology Commentary Source Type: news
Empagliflozin Gets FDA Nod for CKD Without T2D or HF Empagliflozin Gets FDA Nod for CKD Without T2D or HF
The US Food and Drug Administration gave the SGLT2 inhibitor empagliflozin (Jardiance) a new indication for treating adults with isolated chronic kidney disease.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - September 27, 2023 Category: Cardiology Tags: Nephrology News Alert Source Type: news
Postmenopausal Fracture Risk for SGLT2 Inhibitors Similar to Other Diabetes Drugs
(MedPage Today) -- SGLT2 inhibitors were associated with a lower or similar fracture risk compared with incretin-based antidiabetic agents in postmenopausal women with type 2 diabetes, according to a claims-based study involving two independent... (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - September 26, 2023 Category: Cardiology Source Type: news
Are Vitamin D Levels Key to Canagliflozin's Fracture Risk? Are Vitamin D Levels Key to Canagliflozin's Fracture Risk?
Study findings suggest that patients be screened for vitamin D deficiency before starting SGLT2 inhibitor therapy, or they should simply be prescribed vitamin D supplements.Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - September 22, 2023 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news
FDA Approves Another SGLT2 Inhibitor for Treating CKD
(MedPage Today) -- The SGLT2 inhibitor empagliflozin (Jardiance) nabbed a new indication for the treatment of adults with chronic kidney disease (CKD) regardless of diabetes status, Boehringer Ingelheim and Eli Lilly announced.
Data from the phase... (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - September 22, 2023 Category: Cardiology Source Type: news
SGLT2i in Acute Heart Failure, The Earlier The Better? SGLT2i in Acute Heart Failure, The Earlier The Better?
Ileana Pi ña interviews Zachary Cox, PharmD, about the DICTATE-AHF trial on the initiation of the SGLT2 inhibitor, dapagliflozin, early in acute heart failure decompensation.theheart.org on Medscape (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - September 20, 2023 Category: Cardiology Tags: Cardiology Commentary Source Type: news
Mechanisms of SGLT2 Inhibitors and Diuretics in HF Mechanisms of SGLT2 Inhibitors and Diuretics in HF
A new analysis helps clarify our understanding of how SGLT2 inhibitors reduce the risk of adverse outcome in patients with HFpEF, HFmrEF, and HFrEF.European Heart Journal (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 19, 2023 Category: Consumer Health News Tags: Cardiology Journal Article Source Type: news
Newer Glucose-lowering Drugs and Risk of Dementia Newer Glucose-lowering Drugs and Risk of Dementia
Might newer glucose-lowering drugs such as SGLT2 and DPP-4 inhibitors and GLP-1 receptor agonists have beneficial effects on the risk of dementia?Journal of the American Geriatrics Society (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 19, 2023 Category: Consumer Health News Tags: Internal Medicine Journal Article Source Type: news
SGLT2-inhibitors: No Benefit in Hospitalized COVID-19 SGLT2-inhibitors: No Benefit in Hospitalized COVID-19
However, an important take-home message from this new meta-analysis is that these widely used medications appeared to be safe even in acutely ill hospitalized patients, the researchers say.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 13, 2023 Category: Consumer Health News Tags: Cardiology News Source Type: news
SGLT2 Inhibitors: No Benefit in Hospitalized COVID-19 SGLT2 Inhibitors: No Benefit in Hospitalized COVID-19
However, an important take-home message from this new meta-analysis is that these widely used medications appeared to be safe even in acutely ill hospitalized patients, the researchers say.Medscape Medical News (Source: Medscape Internal Medicine Headlines)
Source: Medscape Internal Medicine Headlines - September 13, 2023 Category: Internal Medicine Tags: Cardiology News Source Type: news
Diabetes Drug Class Appears to Reduce Recurrent Gout Flares Diabetes Drug Class Appears to Reduce Recurrent Gout Flares
Previously associated with a lower incidence of gout, sodium-glucose cotransporter-2 (SGLT2) inhibitors for the first time also appear to reduce gout flare recurrence and excess mortality.Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - August 31, 2023 Category: Endocrinology Tags: Rheumatology News Source Type: news
Case Grows for SGLT2 Inhibitors as Gout Treatment
(MedPage Today) -- Patients with gout and type 2 diabetes treated with SGLT2 inhibitors not only had reduced numbers of gout flares, but also lived longer compared with other such patients receiving other medications, researchers said.
Among nearly... (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - August 28, 2023 Category: Cardiology Source Type: news
ESC Backs SGLT2i Plus GLP-1 in Diabetes with High CVD Risk ESC Backs SGLT2i Plus GLP-1 in Diabetes with High CVD Risk
New ESC guidelines recommend using both an SGLT2 inhibitor and a GLP-1 receptor agonist simultaneously to treat people with type 2 diabetes and established cardiovascular disease.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - August 26, 2023 Category: Cardiology Tags: Cardiology News Source Type: news
